$15.15 0.6 3.8%
Last Trade - 16/04/21
| Market Cap | £648.0m |
| Enterprise Value | £519.4m |
| Revenue | £n/a |
| Position in Universe | 2926th / 6850 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Achilles Therapeutics plc is a clinical stage immuno-oncology biopharmaceutical company that is engaged in developing precision T cell therapies to treat multiple types of solid tumors. The Company has developed a bioinformatic platform called PELEUS, which is used to identify clonal neoantigens in patients. The Company's manufacturing process, VELOS, uses the patient’s T cells and blood-derived dendritic cells to create a clonal neoantigen targeting T cell therapy (cNeT). It's pipeline includes two single arm, open-label, proof-of-concept clinical trials in advanced non-small cell lung cancer (NSCLC) and metastatic or recurrent melanoma: CHIRON a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with advanced NSCLC, and THETIS a Phase I clinical trial to evaluate the safety, tolerability and clinical activity of cNeT in up to 60 patients with metastatic or recurrent melanoma.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | November 18, 2020 |
| Public Since | March 31, 2021 |
| No. of Shareholders: | n/a |
| No. of Employees: | 153 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 59,150,955 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 245 Hammersmith Road, LONDON, W6 8PW, United Kingdom |
| Web | https://www.achillestx.com/ |
| Phone | +44 20 81544600 |
| Contact | () |
| Auditors | KPMG LLP |
As of 16/04/21, shares in Achilles Therapeutics are trading at $15.15, giving the company a market capitalisation of £648.0m. This share price information is delayed by 15 minutes.
Shares in Achilles Therapeutics are currently trading at $15.15 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Achilles Therapeutics price has moved by % over the past year.
There are no analysts currently covering Achilles Therapeutics.
Achilles Therapeutics is scheduled to issue upcoming financial results on the following dates:
Achilles Therapeutics does not currently pay a dividend.
Achilles Therapeutics does not currently pay a dividend.
Achilles Therapeutics does not currently pay a dividend.
To buy shares in Achilles Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Achilles Therapeutics are currently trading at $15.15, giving the company a market capitalisation of £648.0m.
Here are the trading details for Achilles Therapeutics:
Based on an overall assessment of its quality, value and momentum, Achilles Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We were not able to load any forecast data for Achilles Therapeutics.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Achilles Therapeutics. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $15.15, shares in Achilles Therapeutics are trading at 1.72% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Achilles Therapeutics.
We were unable to find the directors for Achilles Therapeutics.
Here are the top five shareholders of Achilles Therapeutics based on the size of their shareholding:
